Singapore markets closed

Pacira BioSciences, Inc. (PCRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
30.62+0.01 (+0.03%)
As of 12:55PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close30.61
Open30.56
Bid30.48 x 100
Ask30.76 x 100
Day's range30.23 - 30.92
52-week range25.33 - 42.63
Volume267,275
Avg. volume646,527
Market cap1.425B
Beta (5Y monthly)0.77
PE ratio (TTM)20.28
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029

    TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pacira also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including,

  • GlobeNewswire

    Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes

    TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pacira also intends to grant the initial purchasers of the notes an option to purchase, for

  • GlobeNewswire

    Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program

    -- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2024. First Quarter 2024 Financial Highlights Total revenues of $167.1 millionNet product sales of $132.4 million for EXPAREL, $25.8 million for ZILRETTA, and $5.0 million for iovera°Net income of $9.0 millio